Redwood Pharma AB — Shareholder Meeting (May 2022)
10 slides from Redwood Pharma AB's shareholder meeting presentation, May 10, 2022
Slide 1: 2022 Annual General Meeting
10 May 2022 Presentation: 2022 Annual General Meeting Redwood Pharma 1
Slide 2: 2022: A year of renewal and realignment
2022: A year of renewal and realignment • Redwood Pharma’s mission continues to be the development of Rx and OTC (medical devices) in ophthalmology where unmet medical needs exist • Our current focus is to bring RP501 to market in Europe • Starting RP501 clinical trial in Europe to support a CE-mark
Slide 3: The global pharmaceutical industry continues its strong growth
The global pharmaceutical industry continues its strong growth 3
Slide 4: Pharmaceuticals and medical device industries remain strong
Pharmaceuticals and medical device industries remain strong Revenue of the worldwide pharmaceutical market from 2001 to 2020 • Pharmaceuticals continue strong sales over the last 2 decades • R&D spending has grown from US$ 127bn in 2012 to US$ 200bn in 2020. (in billion U.S. dollars) Source: https:/
Slide 5: The market for ophthalmology products continues to grow
The market for ophthalmology products continues to grow • The global ophthalmology drugs market was valued at USD$ 36.7bn in 2020 • Rising prevalence in eye disorders is expected to boost market growth by 6.4% CAGR through 2028 • Dry eye, AMD, glaucoma are among leading growth areas Source: www.gran
Slide 6: DED market overview
DED market overview Global DED sales by treatment type1 ($bn) $4.5 • Over 50 million people in the US and Europe are thought to suffer from DED, $2.9 one of the most common ocular $2.3 $2.3 diseases • An estimated 55% of DED sufferers $0.4 $0.4 $0.6 consult an eye specialist, who typically $0.2 $0.2
Slide 7: DED – Effective and convenient treatments are needed
DED – Effective and convenient treatments are needed1 There are various underlying causes of DED, and no silver bullet effective for all patients • The first line of therapy is artificial tears, tried by 80% of all sufferers1 • Artificial tears alone are frequently ineffective, and in the absence of
Slide 8: Bringing RP501 to market
Bringing RP501 to market • Solving primary customer needs: efficacy and convenience • RP501 represents a next-generation therapy beyond ordinary artificial tears and gels. Has performance and convenience benefits of both. • Short-term goal: EU regulatory approval to commercialize and launch RP501 •
Slide 9: Challenges for coming 12 months
Challenges for coming 12 months • Successfully completing RP501 clinical trial • Submitting regulatory application for RP501 CE-mark in Europe • Adding a commercial focus with a branded product and exploring new regional partnerships • Finding possible new development projects with primary focus in
Slide 10: Contact Redwood Pharma AB (publ)
CONTACT REDWOOD PHARMA AB (PUBL) Mr. Martin Vidaeus Ringvägen 100e, 9th Floor CEO 118 60 Stockholm, Sweden +46 70 232 29 29 www.redwoodpharma.com Martin.Vidaeus@redwoodpharma.com Nasdaq First North Growth stock market: REDW.ST 10